Robert E. Landry - 01 Dec 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role: EVP Finance CFO
Signature: /s/**Robert E. Landry
Issuer symbol: REGN
Transactions as of: 01 Dec 2022
Net transactions value: -$943,825
Form type: 4
Filing time: 02 Dec 2022, 15:05:43 UTC
Previous filing: 02 Nov 2022
Next filing: 12 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	REGN	Common Stock	Options Exercise	$954,800	+2,500	+8.7%	$381.92	31,244	01 Dec 2022	Direct	F1
transaction	REGN	Common Stock	Tax liability	$1,437,062	-1,890	-6%	$760.35	29,354	01 Dec 2022	Direct	F1
transaction	REGN	Common Stock	Sale	$440,283	-582	-2%	$756.50	28,772	02 Dec 2022	Direct	F1
transaction	REGN	Common Stock	Sale	$12,158	-16	-0.06%	$759.90	28,756	02 Dec 2022	Direct	F1
transaction	REGN	Common Stock	Sale	$9,122	-12	-0.04%	$760.19	28,744	02 Dec 2022	Direct	F1
holding	REGN	Common Stock						250	01 Dec 2022	By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REGN	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-2,500	-27%	$0.000000	6,800	01 Dec 2022	Common Stock	2,500	$381.92	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2	The stock option award vests in four equal annual installments, commencing one year after the date of grant.